Rapid methods have been available to the pharmaceutical industry for decades. And although global regulations have changed to encourage their use, especially for rapid sterility testing, and the compendia enhanced their chapters to promote the validation and implementation of these technologies, only a handful of firms have embraced rapid methods to their fullest potential. This presentation, which will include audience participation, will once and for all disprove the misconceptions and address any confusion surrounding rapid method applications and acceptance. We will also discuss the most current enablers, including guidance from USP, Ph. Eur., Annex 1, FDA and EMA, and share successful case studies where rapid methods have had the greatest impact.